Evidence map›Paper›PMID 26238782›Full record

ArticleCancer research2015

The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.

Paul William Harms, Pankaj Vats, Monique Elise Verhaegen, Dan R Robinson, Yi-Mi Wu, Saravana Mohan Dhanasekaran, Nallasivam Palanisamy, Javed Siddiqui, Xuhong Cao, Fengyun Su and 10 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 3 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 3 syntheses or guidelines pooled it, 339 citations in OpenAlex.

  1. Pooled it
  2. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  3. Pooled it
  4. Trial
  5. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  6. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Diagnostic Utility and Clinicopathologic Associations of Histone H3 Lysine 27 Trimethylation (H3K27me3) Immunohistochemistry for Merkel Cell Carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  15. Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Paul William Harms *Michigan Center for Translational Pathology, University of Michigan Medical School.
Pankaj Vats *Michigan Center for Translational Pathology, University of Michigan Medical School.
Monique Elise VerhaegenDepartment of Dermatology, University of Michigan Medical School.
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan Medical School.
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan Medical School.
Saravana Mohan DhanasekaranMichigan Center for Translational Pathology, University of Michigan Medical School.
Nallasivam PalanisamyMichigan Center for Translational Pathology, University of Michigan Medical School.
Javed SiddiquiMichigan Center for Translational Pathology, University of Michigan Medical School.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan Medical School.
Fengyun SuMichigan Center for Translational Pathology, University of Michigan Medical School.
Rui WangMichigan Center for Translational Pathology, University of Michigan Medical School.
Hong XiaoMichigan Center for Translational Pathology, University of Michigan Medical School.
Lakshmi P KunjuMichigan Center for Translational Pathology, University of Michigan Medical School.
Rohit MehraMichigan Center for Translational Pathology, University of Michigan Medical School.
Scott A TomlinsMichigan Center for Translational Pathology, University of Michigan Medical School.
Douglas Randall FullenDepartment of Pathology, University of Michigan Medical School.
Christopher Keram BichakjianDepartment of Dermatology, University of Michigan Medical School.
Timothy M JohnsonDepartment of Dermatology, University of Michigan Medical School.
Andrzej Antoni DlugoszDepartment of Dermatology, University of Michigan Medical School.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan Medical School.
University of Michigan–Ann Arbor · US

Funding

Sequencing, Analysis, and Interpretation of SequencingUM1HG006508 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J., ROBERTS, SCOTT · 2013 to 2016
$7.8M
Merkel cell polyomavirus T antigens in tumorigenesisR01CA189352 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DLUGOSZ, ANDRZEJ A., VERHAEGEN, MONIQUE ELISE · 2015 to 2019
$1.8M
Merkel cell polyomavirus T antigens and cancerR21CA183084 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DLUGOSZ, ANDRZEJ A. · 2014 to 2015
$371k
Howard Hughes Medical InstituteNCI NIH HHS R01 CA189352NCI NIH HHS R21 CA183084NHGRI NIH HHS UM1 HG006508
6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine tumor. Merkel cell polyomavirus (MCPyV) may contribute to tumorigenesis in a subset of tumors via inhibition of tumor suppressors such as retinoblastoma (RB1) by mutated viral T antigens, but the molecular pathogenesis of MCPyV-negative MCC is largely unexplored. Through our MI-ONCOSEQ precision oncology study, we performed integrative sequencing on two cases of MCPyV-negative MCC, as well as a validation cohort of 14 additional MCC cases (n = 16). In addition to previously identified mutations in TP53, RB1, and PIK3CA, we discovered activating mutations of oncogenes, including HRAS and loss-of-function mutations in PRUNE2 and NOTCH family genes in MCPyV-negative MCC. MCPyV-negative tumors also displayed high overall mutation burden (10.09 ± 2.32 mutations/Mb) and were characterized by a prominent UV-signature pattern with C > T transitions comprising 85% of mutations. In contrast, mutation burden was low in MCPyV-positive tumors (0.40 ± 0.09 mutations/Mb) and lacked a UV signature. These findings suggest a potential ontologic dichotomy in MCC, characterized by either viral-dependent or UV-dependent tumorigenic pathways.

Indexed as

MutationOncogenesAgedCarcinoma, Merkel CellCarrier ProteinsCell Transformation, NeoplasticDNA Mutational AnalysisDNA, NeoplasmExomeGene Expression ProfilingHumansMaleMembrane ProteinsMerkel cell polyomavirusMiddle AgedNeoplasm ProteinsCarrier ProteinsDNA, NeoplasmGPRIN2 protein, humanMembrane ProteinsNeoplasm ProteinsNerve Tissue ProteinsOncogene Proteins, FusionPRUNE2 protein, humanReceptors, Notch

Identifiers

PMID26238782
PMCPMC4573907
OpenAlexW1914106955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.